Assessment of Efficacy of KAN-JANG® in Mild COVID-19

Launched by SWEDISH HERBAL INSTITUTE AB · Apr 14, 2021

Keywords

ClinConnect Summary

Rationale. Pathogenesis and progression of COVID-19 is a multistep process, which requires correct therapeutic strategy on various steps of initiation of overall defense response to pathogen and its resolution. Consequently, effective treatment of COVID-19 requires pharmaceutical corrections of many components innate, adaptive immune system, phases I-III metabolizing enzymes of detoxifying and repairing systems, and the SARS-Cov-2 virus' life cycle and proliferation.

It can be achieved by multitarget pharmaceutical intervention of herbal preparations with polyvalent and pleiotropic actions...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Laboratory confirmed (SARS-Cov-2 PCR-positive test) mild COVID-19 infection (in the last three days),
• • COVID-19 patient in stable, moderate condition (i.e., not requiring Intensive Care Unit (ICU) admission).
• • Subjects must be under observation or admitted to a controlled facility or hospital (home quarantine is not sufficient).
• • Able to take medication alone
• • Able to give informed consent.
• Exclusion Criteria:
• • Pulmonary diseases
• • Chronic pulmonary diseases
• • Chronic rhinosinusitis
• • Patient admitted already under invasive mechanical ventilation;
• • The patient admitted with the severe acute respiratory syndrome and diagnosed with an etiologic agent other than Covid 19;
• • Renal failure requiring dialysis or creatinine ≥ 2.0mg/dl;
• • Tube feeding or parenteral nutrition.
• • Respiratory decompensation requiring mechanical ventilation.
• • Uncontrolled diabetes type 2.
• • Hypertension stage 3,
• • Autoimmune disease.
• • Pregnant or lactating women.
• • Patients are taking antibiotics for a reason other than COVID-19 at enrollment.
• • Has a chronically weakened immune system (AIDS, lymphoma, chemo-radio- corticosteroid therapy, immunosuppressive pathology);
• • Patients treated with chemo-radio-corticosteroid therapy in the last six months.
• • Patients with active cancer.
• • Taking immunosuppressive drugs (e.g., anti-rejection treatment after organ transplant);
• • Already participating in another clinical trial;
• • Has any other condition that would prevent safe participation in the study.